LiveLoadingtotal visitors

Open source
Comparisons

Treatment options: different targets, different outcomes

Compare insulin, noninsulin medication, metabolic surgery, technology, and investigational cell therapy by the problem each addresses.

2 min readEasy read4 sourcesChecked 30 Sept 2026Established

By The Diabetes Guide editorial project · Updated 30 Sept 2026

On this page
In simple words

Insulin, other medicines, surgery, automated pumps and cell replacement each aim at a different target.

  1. Step 1: Different targets

    Some replace insulin, some lower liver sugar, some change weight or automate delivery.

    For example: Different tools for different problems.

  2. Step 2: What remains

    Each choice leaves something to watch: lows, side effects, surgery risks, supplies or immune drugs.

    For example: Every trade has a price.

  3. Step 3: Do not rank blindly

    Trial results measure different things, such as sugar, weight or kidney events.

    For example: Comparing apples and oranges by weight only would miss the taste.

Remember: There is no single “best” treatment for everyone.

The full story

Want more? Below is the detailed version with the real science words. It is fine to skip it.

ApproachMain targetWhat remains
InsulinInadequate insulin supplyMonitoring, hypoglycemia prevention and ongoing access
Noninsulin medicinesLiver, kidney, secretion, appetite or sensitivity pathwaysAgent-specific risks and ongoing assessment
Metabolic surgeryWeight and broader metabolic physiologyProcedure risk and lifelong nutritional care
Automated deliveryFeedback between sensing and insulin deliveryBiological disease and device/supply risks
Cell replacementMissing beta-cell functionImmune protection, durability, safety and scale
1 2 3 4

Avoid a single league table

The “best” therapy depends on the person's disease type, organs, goals and circumstances. Trial endpoints are not interchangeable: HbA1c, weight loss, kidney events and insulin independence answer different questions.

Trace the evidence

Sources and further reading

3.Diabetes Technology: Standards of Care 2026 (opens in a new tab)

American Diabetes Association · 2026 · Guideline

Strong Evidence
Who was studied, limits and source check

Limitations: Access, training, device labeling, and safe-use capacity affect applicability.

Source checked 2026-09-30. See the original publication for full methods.

4.Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes (opens in a new tab)

Reichman et al.; New England Journal of Medicine · 2025 · Early human study

Preliminary
Who was studied, limits and source check

Population: Selected adults with T1D, severe hypoglycemia and impaired awareness

Sample: 14 with ≥12-month follow-up; 12 at full dose

Limitations: Small, uncontrolled interim analysis; required immunosuppression; serious adverse events and deaths occurred. Not a routine cure.

Source checked 2026-09-30. See the original publication for full methods.

Source checking is an editorial literature check, not independent medical review. This page is for learning. It cannot diagnose you or make a treatment plan. Evidence labels describe the cited claims, not the whole topic.

What does “Established” mean?

Doctors and scientists agree. This is well known. Like “the sun rises in the east”.

Keep reading

The body

The one-page mental model

Diabetes means there is too much sugar in the blood for too long, because the body does not have enough insulin or cannot use it well.

4 minEasy read

Type 1

Type 1 diabetes: the complete journey

Type 1 diabetes is usually an autoimmune condition. The body’s defence system harms the beta cells, so less and less insulin is made.

4 minEasy read